Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature Medicine 10, 1329 - 1335 (2004)
Published online: 7 November 2004 | doi:10.1038/nm1134
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells
Jose M Polo1, Tania Dell'Oso1, Stella Maris Ranuncolo1, Leandro Cerchietti1, David Beck1, Gustavo F Da Silva1, Gilbert G Prive2, Jonathan D Licht3 & Ari Melnick1
Abstract
The BTB/POZ transcriptional repressor and candidate oncogene BCL6 is frequently misregulated in B-cell lymphomas. The interface through which the BCL6 BTB domain mediates recruitment of the SMRT, NCoR and BCoR corepressors was recently identified. To determine the contribution of this interface to BCL6 transcriptional and biological properties, we generated a peptide that specifically binds BCL6 and blocks corepressor recruitment in vivo. This inhibitor disrupts BCL6-mediated repression and establishment of silenced chromatin, reactivates natural BCL6 target genes, and abrogates BCL6 biological function in B cells. In BCL6-positive lymphoma cells, peptide blockade caused apoptosis and cell cycle arrest. BTB domain peptide inhibitors may constitute a novel therapeutic agent for B-cell lymphomas.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A peptide aptamer to antagonize BCL-6 functionOncogene Original Article
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATRNature Immunology Article (01 Jul 2007)
Acetylation inactivates the transcriptional repressor BCL6Nature Genetics Article (01 Dec 2002)
Functional interaction of HTLV-1 Tax protein with the POZ domain of the transcriptional repressor BCL6Oncogene Original Article
See all 38 matches for Research